Clinical Trials | June 14, 2024
Moderna announces positive Phase 3 efficacy data for next generation COVID-19 vaccine
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery
Subscribe To Our Newsletter & Stay Updated
